Interim results for the six months ended 30 April, released today, show H1 order intake growth was an encouraging 9% vs H1 FY24, although Idox’s licensing cycle meant that revenue growth was 4% to £45.0m. Adjusted EBITDA increased by 6% to £13.9m while reported profit grew by 14% to £6.4m. Adjusted diluted EPS increased by 17% to 1.48p. Cash generation was strong, with period-end net cash at £0.2m. The statement reports good progress on M&A, with encouraging current trading and business pipeline.